novo nordisk ozempic - Search News

News

Novo Nordisk, Ozempic

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

24/7 Wall St. · 3d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The announcement,

Investing.com · 1d

Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug Wegovy, going down from May’s 21% growth projection to just a 14% sales increase throughout 2025.

Novo Nordisk Gave Up Its Weight-Loss Gains

Bloomberg on MSN · 17h

How Novo Nordisk Gave Up Its Weight-Loss Gains

For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes,

Opinion

The Wall Street Journal · 1d

Novo Nordisk’s Weight Loss Lesson

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Hosted on MSN · 13h

Novo Nordisk shares dip further as Wegovy gains nearly erased

By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.

Ozempic Maker’s Stock Plunges 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

10h

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

3don MSN

Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting

U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

WFRV Local 5 on MSN9h

New tariffs could raise prices of Ozempic, Wegovy

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

1don MSN

Why Novo Nordisk Stock Crumbled Again Today

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...

8hon MSN

Medicare Update: Trump Admin Launching Pilot Program to Cover Ozempic

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

10hon MSN

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results